Comparison of two regimens of policosanol administered at 20 mg/d in patients with type II hypercholesterolemia: A randomized, double-blind, placebo-controlled study

Current Therapeutic Research - Clinical and Experimental

Volumn 62, Issue 3, 2001, Pages 194-208

  Castaño, Gladys ^a   Más, Rosa ^b   Fernández, Lilia ^b   Illnait, José ^b   Gámez, Rafael ^b   Fernández, Julio C ^b  

^a Center for Medical Surgical Research   (Cuba)

^b NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

Author keywords

Cholesterol lowering drugs; Higher aliphatic primary alcohols; Hypercholesterolemia; Lipid lowering therapy; Policosanol

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; POLICOSANOL;

ADULT; AGED; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TABLET; TREATMENT OUTCOME;

EID: 0035060556     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(01)80031-X     Document Type: Article

References (54)

1. Cardiovascular disease epidemiology. A journey from the past into the future
2. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults
3. Prevention of coronary heart disease in clinical practice: Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension
4. Prevention of coronary heart disease in clinical practice. Recommendations of the Second Joint Task Force of European and other Societies on coronary prevention
5. European and American recommendations for coronary heart disease prevention
6. An updated coronary risk profile. A statement for health professionals
7. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease
8. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering
9. Helsinki Heart Study: Primary-prevention with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
10. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
11. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
12. Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) study. Clinical implications for cardiovascular practice
13. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
14. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
15. Policosanol
16. Efficacy and safety of policosanol in patients with primary hypercholesterolemia
17. Effects of successive dose increases of policosanol on the lipid profile and tolerability of treatment
18. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolaemia and tolerability to treatment
19. One-year efficacy and safety of policosanol in patients with type II hypercholesterolemia
20. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia
21. One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia
22. One year study on the effect of policosanol (5 mg twice a day) on lipid profile in patients with type II hypercholesterolemia
23. Efficacy and tolerability of policosanol in elderly patients with type II hypercholesterolemia: A 12-month study
24. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia
25. Effects of policosanol in hypertensive patients with type II hypercholesterolemia
26. Effects of policosanol on hypercholesterolemic patients with abnormal serum biochemical indicators of hepatic function
27. A comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia
28. A comparative study of policosanol versus pravastatin in patients with type II hypercholesterolemia
29. Effects of policosanol on primary hypercholesterolemia: A 3-year open-extension follow-up
30. Open-label study of the efficacy, safety and tolerability of policosanol in patients with high global coronary risk
31. Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors
32. A long-term, open-label study of the efficacy and tolerability of policosanol in patients with high global coronary risk
33. Effects of policosanol and pravastatin on lipid profile, platelet aggregation and endothelemia in older hypercholesterolemic patients
34. Efficacy and tolerability of policosanol compared with lovastatin in patients with type II hypercholesterolemia and concomitant risk factors
35. Effect of policosanol on postmenopausal women with type II hypercholesterolemia
36. Effect of policosanol in older patients with type II hypercholesterolemia and high coronary risk
37. Treatment of hypercholesterolemia in NIDDM with policosanol
38. Effect of policosanol on patients with non-insulin-dependent diabetes mellitus and hypercholesterolemia: A pilot study
39. Comparative study of the efficacy and tolerability of policosanol and lovastatin in patients with hypercholesterolemia and non-insulin-dependent diabetes mellitus
40. Pharmacoepidemiologic study of policosanol
41. Policosanol: Results of a postmarketing surveillance control of 27,879 patients
42. Policosanol inhibits cholesterol biosynthesis and enhances low-density lipoprotein processing in cultured human fibroblasts
43. Effect of policosanol on the hepatic cholesterol biosynthesis of normocholesterolemic rats
44. Cholesterol-lowering effect of policosanol on rabbits with hypercholesterolaemia induced by a wheat starch-casein diet
45. Estimation of the concentration of lowdensity lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge
46. Separation of serum high-density lipoprotein for cholesterol de-termination: Ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride
47. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals
48. Statistical considerations for performing multiple tests in a single experiment. 5. Comparing two therapies with respect to several endpoints
49. Mevalonic acid in human plasma: Relationship of concentration and circadian rhythm to cholesterol synthesis in man
50. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia
51. Cost of treating to a modified European Atherosclerosis Society LDL-C target. Comparison of atorvastatin with fluvastatin, pravastatin and simvastatin
52. LIPI-WATCH, a Belgian/Luxembourg survey on achievement of European Atherosclerosis Society lipid goals